The recent development of a powerful and flexible genome editing technique (the CRISP-cas9 method) accelerates tremendously the production of animal models and will significantly enhance the perspectives of (somatic) gene ...

According to recent reports, the success rate of targeted therapy directed by “actionable mutations” found in tumour DNA is rather low (10 to 20%). Interesting attempts have been made to improve this by establishing mouse ...

A practical DNA sequencer based on nanopores has now demonstrated interesting performance and may be on the way to capturing a significant slice of the sequencing market while opening up new application fields thanks to ...

The summit organised in early December 2015 considered in depth the various issues (technical, scientific, societal and ethical) raised by the prospect of genome editing using the extremely effective CRISPR system. Germline ...

The recently announced “Cancer moonshot” may be greeted with scepticism: the previous “War on cancer” (1971) was not very successful. However the current plan seems well targeted, with emphasis not only on research investment ...

After clearing many hurdles, gene therapy is now reaching the commercialization stage and can be expected to make a modest but real contribution to treatment in the near future.

Targeted modification of genes (“gene editing”) is made much easier by the recently developed CRISPR-Cas9 system. This has raised alarm about possible uses of this technology for germline modification of the human genome; ...

A Genome Wide Association Study on propensity to motion sickness published by 23andMe gives interesting results, shows validity for self-reported phenotypic information and underlines the value of the model developed by ...

The detection and analysis of circulating tumour DNA and/or circulating tumour cells in the blood of cancer patients open new possibilities for cancer characterisation and management. The approach has generated much ...